{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105485","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.072765+00:00","generated_at":"2026-05-17T16:44:55.976249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3","bullets":["Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.","Cash and equivalents $5.2M at June 30, 2025, down from $6.5M at Dec 31, 2024; funds operations through Dec 2025.","Completed dosing in Phase 1b Gemini study in CKD; topline data expected later Q3 2025.","Raised $4M gross proceeds from public offering in May 2025.","Cash used in operations was $4.7M in Q2 2025 vs. $5.3M in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105485","json":"https://secwatch.observer/filing/0000950170-25-105485.json","markdown":"https://secwatch.observer/filing/0000950170-25-105485.md","text":"https://secwatch.observer/filing/0000950170-25-105485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/0000950170-25-105485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:44:55.976249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}